Pain is estimated to affect about 30% of the world’s population and treatment is challenging because of issues with addiction and withdrawal which accompany many current analgesics. Human TRPV1 is a widely expressed nociceptor and is a desirable target to modulate diverse human pathophysiologies, including pain, obesity, and diabetes, among others....